Taipei, Taiwan – November 26, 2024
Advanced Genomics APAC (AGL APAC) is pleased to announce a strategic partnership with South Korea-based 3BIGS to bring advanced cancer genomic testing services to the Asia-Pacific market.
Through this collaboration, AGL APAC will strengthen its commitment to providing cutting-edge solutions for comprehensive genomic profiling (CGP) for cancer therapy and hereditary cancer. By integrating 3BIGS’ expertise in AI-powered bioinformatics and data analysis with Nonacus GALEAS technologies, the partnership will deliver enhanced cancer diagnostic services tailored to the region’s needs.
The collaboration focuses on developing cancer gene panels and bioinformatics pipelines optimized for clinicians and researchers, ensuring reliable and actionable insights across the Asia-Pacific region. With over 9.8 million new cancer cases annually in the region and incidence rates rising by 2% per year, this partnership addresses the growing demand for scalable and cost-effective diagnostic solutions.
“This partnership represents a significant milestone for AGL APAC as we continue to expand our footprint in the Asia-Pacific region,” said Andy Chang, Director of AGL APAC. “By leveraging the strengths of both companies, we aim to accelerate access to cutting-edge cancer diagnostics and support clinicians in delivering personalized treatment strategies.”
Together, AGL APAC and 3BIGS remain committed to advancing healthcare through precision diagnostics, ensuring the Asia-Pacific market benefits from the latest developments in cancer genomics and bioinformatics innovation.
For more details, please refer to the EIN Presswire|Newsmatics release below:
https://www.einpresswire.com/article/763535898/advanced-genomics-apac-announces-partnership-with-3bigs-to-expand-cancer-genomic-testing-services-across-asia-pacific
(If you cannot access the above link, please enter the URL directly)
About Advanced Genomics APAC
Advanced Genomics APAC Co. Ltd. provides cutting-edge genetic testing solutions across the Asia-Pacific region. As a subsidiary of Advanced Genomics Limited (UK), the company focuses on innovation and excellence to meet the rising demand for genetic testing services, enhance early cancer detection, and strengthen the accuracy of cancer diagnostics through strategic partnerships and advanced technology.
About Nonacus
Nonacus, a subsidiary of Advanced Genomics Limited (UK), specializes in the development of advanced genetic analysis products. The company is committed to providing innovative solutions that enhance early detection and personalized treatment of various medical conditions, including the GALEAS products.
Contact Information
For media inquiries, please contact:
Advanced Genomics APAC Co. Ltd.
Phone: +886 32870503
Email: infoapac@nonacus.com
For More Information
For more information about our new products and services, visit our website at aglapac.com
